Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lung Cancer: early-phase trial registry
146 of 430 indexed Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #12 of 28,707 conditions by registered trial count.
430 US clinical trials · 146 currently recruiting · #12 of 28,707 conditions by registered trial count
Lung Cancer: 430 US clinical trials tracked, 146 recruiting.
Lung Cancer is the subject of 430 registered US clinical trials on ClinicalTrials.gov, 146 of them currently open to new participants. 23 are in Phase 3-4 (later-stage) and 181 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 36 of these trials.
Enrollment posture brief
Registry condition lung-cancer
OPEN 146 | RECR 34% | LATE 23 | EARLY 181 | RANK #12 | SPON 36
Volume-matched condition peers
Nearest open-share peer: Solid Tumors (34% recruiting · 127 trials)
Lung Cancer lists 146 open slots (34% of 430 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lung Cancer is recruiting below its size-band peers.
146 of 430 indexed trials (34%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Lung Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 36 of 430 trials (8.4%). 179 distinct sponsors appear on at least one study for this condition label.
-
Typical Lung Cancer enrolment sits around 89 participants.
Median target enrolment is 89 among the 410 trials that report a genuine target (sentinel values excluded). 212 of those (51.7%) plan for fewer than 100 participants.
-
Lung Cancer research is mostly interventional.
321 interventional and 109 observational studies make up this index (74.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
430 total, page 9 of 9
Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
NCT00541099
Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
National Cancer Institute (NCI)
NCT03384316
Tracking of Respiratory-Induced Tumor Motion Using Implanted Fiducials
M.D. Anderson Cancer Center
NCT00500513
Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON)
Memorial Sloan Kettering Cancer Center
NCT00577707
Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer
Shionogi
NCT00078390
A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors
Case Comprehensive Cancer Center
NCT02978586
A Prospective Study to Evaluate Continuous Positive Airway Pressure Devices to Reduce Pulmonary Dose
Case Comprehensive Cancer Center
NCT05142358
Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Gundersen Lutheran Health System
NCT00083161
The Science of the Art of Palliative Care
Dartmouth-Hitchcock Medical Center
NCT05137782
Study of 18F-Fluoro-PEG6-IPQA
M.D. Anderson Cancer Center
NCT01320059
Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
NCT00248482
Microdevice for Evaluating Drug Response in Site in Lung Lesions
Oliver Jonas
NCT03972228
Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Case Comprehensive Cancer Center
NCT00041015
Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer
City of Hope Medical Center
NCT00008372
Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
GlaxoSmithKline
NCT00005865
Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
NCT00041314
HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, Maryland: A Pilot Study of Biomarkers
National Cancer Institute (NCI)
NCT00491335
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer
University of Washington
NCT00005023
Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
SWOG Cancer Research Network
NCT00006484
R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
Mayo Clinic
NCT00005989
Lung Screening Study
National Cancer Institute (NCI)
NCT00006382
Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
NCT00072072
Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
NCT00020007
Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer
Pfizer
NCT00005093
Photodynamic Therapy Plus Brachytherapy in Treating Patients With Lung Cancer
Roswell Park Cancer Institute
NCT00014066
Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
NCT00005806
Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery
National Cancer Institute (NCI)
NCT00091039
Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
Radiation Therapy Oncology Group
NCT00081302
Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer
Astex Pharmaceuticals
NCT00005872
Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer
National Cancer Institute (NCI)
NCT00019201
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 85 |
| Phase 2 | 96 |
| Phase 3 | 22 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lung Cancer page
430 registered trials, 146 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 146 Lung Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Lung Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lung Cancer condition card totals 430 registered trials; most-linked intervention paclitaxel; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.